EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prostate zonal impact of 5α‐reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer

Arighno Das, Marcelo Bigarella, Krista Brackman iD, Glenn O Allen, Soroush Rais-Bahrami, Kayla Bahr, Emily Schmitt, Andrew M Fang, Hunter Boudreau, Christopher P Filson iD, Melina Pectasides, Giuseppe V Toia und 1 weitere

BJU International · 2026-02 · 137 (2) · 332-338

DOI: 10.1111/bju.70067 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 05.11.2025. Verfasst von Arighno Das und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, 5-alpha Reductase Inhibitors, Multiparametric Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: John Livesey Family.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the impact of 5α‐reductase inhibitors (5‐ARIs) on multiparametric magnetic resonance imaging (mpMRI) features of Prostate Imaging‐Reporting and Data System (PI‐RADS) lesions and their influence on the detection of clinically significant prostate cancer (csPCa), with a focus on differences between prostate zones. Patients and Methods We retrospectively reviewed data from 1108 PI‐RADS version 2 score 3–5 lesions in 718 patients across a multi‐institutional cohort, all of whom underwent magnetic resonance imaging (MRI)‐targeted biopsy. A subset of 66 lesions from patients receiving 5‐ARI therapy was matched to lesions from untreated patients and independently reviewed by an experienced radiologist in a blinded fashion. Apparent diffusion coefficient (ADC) values were quantified for each lesion and for peripheral and transition zones.

Results

Among the 1108 lesions, 90 (8%) were in patients on 5‐ARI therapy for ≥3 months prior to mpMRI. Multivariable analysis demonstrated that 5‐ARI use was associated with significantly reduced odds of detecting csPCa on targeted biopsy (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.18–0.57). Stratified analysis revealed a pronounced reduction in csPCa detection in peripheral zone lesions (OR 0.20, 95% CI 0.05–0.68), but not in transition zone lesions (OR 0.38, 95% CI 0.11–1.18). Blinded radiological review showed higher mean ADC values in peripheral zone lesions among 5‐ARI users (869 vs 765 mm 2 /s; P = 0.04) and lower lesion conspicuity ( P = 0.027). There were no significant imaging differences in the transition zone.

Conclusions

Treatment with 5‐ARIs is associated with decreased detection of csPCa on MRI‐targeted biopsy, especially for peripheral zone lesions. These effects may be attributable to increased ADC values and reduced lesion conspicuity, suggesting a potential increase in false‐positive mpMRI findings in patients receiving 5‐ARIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms5-alpha Reductase InhibitorsMultiparametric Magnetic Resonance ImagingProstateHumansMaleRetrospective StudiesAgedMiddle AgedImage-Guided Biopsy

Stichwörter der Autor:innen

5α‐reductase inhibitorapparent diffusion coefficientmultiparametric MRIprostate biopsyprostate cancer

Substanzen

5-alpha Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
  • Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.
  • Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.
  • Winship Cancer Institute, Emory Healthcare, Atlanta, GA, USA.

ORCID-Profile: Krista Brackman, Christopher P Filson, David F Jarrard

Förderung

  • John Livesey Family

Zitieren

APA

Das, A., Bigarella, M., Brackman, K., Allen, G. O., Rais-Bahrami, S., Bahr, K., Schmitt, E., Fang, A. M., Boudreau, H., Filson, C. P., Pectasides, M., Toia, G. V., & Jarrard, D. F. (2026). Prostate zonal impact of 5α‐reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer. BJU International, 137(2), 332-338. https://doi.org/10.1111/bju.70067

Vancouver

Das A, Bigarella M, Brackman K, Allen GO, Rais-Bahrami S, Bahr K, et al. Prostate zonal impact of 5α‐reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer. BJU International. 2026;137(2):332-338. doi:10.1111/bju.70067

BibTeX
@article{Das2026,
  author = {Das, Arighno and Bigarella, Marcelo and Brackman, Krista and Allen, Glenn O and Rais-Bahrami, Soroush and Bahr, Kayla and Schmitt, Emily and Fang, Andrew M and Boudreau, Hunter and Filson, Christopher P and Pectasides, Melina and Toia, Giuseppe V and Jarrard, David F},
  title = {Prostate zonal impact of 5α‐reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer},
  journal = {BJU International},
  year = {2026},
  volume = {137},
  number = {2},
  pages = {332--338},
  doi = {10.1111/bju.70067}
}
Kostenlos starten →